看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | -26.0x - -28.8x | -27.4x |
| Selected Fwd P/E Multiple | -1.8x - -2.0x | -1.9x |
| Fair Value | ¥22.73 - ¥25.12 | ¥23.93 |
| Upside | 23.2% - 36.2% | 29.7% |
| Benchmarks | - | Full Ticker |
| Hubei Guangji Pharmaceutical Co., Ltd. | 95,200.0% | SZSE:000952 |
| Hainan Haiyao Co., Ltd. | 56,600.0% | SZSE:000566 |
| Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd | 60,067,100.0% | SHSE:600671 |
| Zhejiang Hisun Pharmaceutical Co., Ltd. | 60,026,700.0% | SHSE:600267 |
| Jiangsu Yahong Meditech Co., Ltd. | 68,817,600.0% | SHSE:688176 |
| Shaanxi Kanghui Pharmaceutical Co., Ltd. | 60,313,900.0% | SHSE:603139 |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| 952 | 566 | 600671 | 600267 | 688176 | 603139 | |||
| SZSE:000952 | SZSE:000566 | SHSE:600671 | SHSE:600267 | SHSE:688176 | SHSE:603139 | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| 3Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| Latest Twelve Months | -534.3% | -806.3% | 77.6% | -103.4% | 3.2% | -5.1% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 0.5% | -28.5% | -27.3% | 3.0% | -849788.7% | -0.4% | ||
| Prior Fiscal Year | 6.3% | 0.6% | -62.0% | 4.1% | -2911.5% | -12.8% | ||
| Latest Fiscal Year | -19.0% | -7.2% | -31.4% | -0.9% | -192.3% | -3.9% | ||
| Latest Twelve Months | -34.2% | -36.6% | -9.1% | -0.2% | -192.3% | -12.2% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | -66.6x | -163.9x | -235.8x | 9.3x | -8.9x | 197.4x | ||
| Price / LTM Sales | 3.0x | 5.9x | 8.8x | 1.1x | 23.6x | 3.1x | ||
| LTM P/E Ratio | -8.6x | -16.0x | -97.3x | -504.1x | -12.3x | -25.1x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | -504.1x | -16.0x | -8.6x | |||||
| Historical LTM P/E Ratio | -26.7x | 41.9x | 83.0x | |||||
| Selected P/E Multiple | -26.0x | -27.4x | -28.8x | |||||
| (x) LTM Net Income | (74) | (74) | (74) | |||||
| (=) Equity Value | 1,917 | 2,018 | 2,119 | |||||
| (/) Shares Outstanding | 99.9 | 99.9 | 99.9 | |||||
| Implied Value Range | 19.19 | 20.20 | 21.21 | |||||
| FX Rate: CNY/CNY | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 19.19 | 20.20 | 21.21 | 18.45 | ||||
| Upside / (Downside) | 4.0% | 9.5% | 15.0% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | 952 | 566 | 600671 | 600267 | 688176 | 603139 | |
| Value of Common Equity | 2,005 | 6,098 | 1,414 | 10,331 | 4,752 | 1,843 | |
| (/) Shares Outstanding | 349.9 | 1,297.4 | 121.8 | 1,168.7 | 561.6 | 99.9 | |
| Implied Stock Price | 5.73 | 4.70 | 11.61 | 8.84 | 8.46 | 18.45 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 5.73 | 4.70 | 11.61 | 8.84 | 8.46 | 18.45 | |
| Trading Currency | CNY | CNY | CNY | CNY | CNY | CNY | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |